Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 05 2025
0mins
Source: Newsfilter
Regulatory Approval: Scinai Immunotherapeutics has received regulatory clearance from the Italian government to acquire 100% of Pincell S.r.l., marking a significant step in the acquisition process, although further conditions must still be met before finalization.
Development Plans: In anticipation of the acquisition, Scinai's Polish subsidiary has applied for a €12 million grant to support the development of Pincell's lead candidate, PC111, which targets severe dermatological conditions and has already received Orphan Drug Designation.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy SCNI?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on SCNI
About SCNI
Scinai Immunotherapeutics Ltd, formerly known as BiondVax Pharmaceuticals Ltd is an Israel-based biopharmaceutical company that is principally focused on developing, manufacturing, and commercializing medical products for the prevention and treatment of autoimmune and infectious diseases but also for other illnesses. The Company’s core focus is to develop NanoAbs for the treatment of various diseases such as COVID-19, psoriasis, and asthma. The Company's product NanoAb is based on alpaca-derived nanosized antibodies (NanoAbs), also known as VHH-antibodies. Additionally, the Company offers manufacturing facilities, aseptic fill and finish suites, laboratories, and experienced professionals for other research and development companies. Scinai Immunotherapeutics Ltd operates in Israel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai's CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week in Tel Aviv, focusing on Israel's biopharma manufacturing capabilities and their impact on the industry, particularly in early development and clinical manufacturing.
- Manufacturing Capability Assessment: The roundtable will examine the current state of Israel's biopharma development ecosystem, emphasizing GMP manufacturing for clinical supply amidst increasing global complexity in biopharma manufacturing, highlighting the need for enhanced local capabilities.
- Diverse Participation: Representatives from government, public agencies, international biopharma manufacturers, and investors are expected to participate, fostering in-depth dialogue and collaboration on the future development of Israel's biopharma sector.
- Strategic Importance: By discussing the infrastructure and manufacturing capabilities in Israel's biopharma sector, the roundtable aims to provide practical insights that will help companies maintain competitiveness and attract investment over the next 5-10 years.
Continue Reading
Scinai CEO to Co-Lead Biopharma Roundtable at HealthIL Week 2026
- Industry Discussion: Scinai Immunotherapeutics CEO Amir Reichman will co-lead a roundtable on January 19, 2026, during HealthIL Week at Expo Tel Aviv, aimed at facilitating a realistic discussion on Israel's biopharma development and manufacturing ecosystem.
- Infrastructure Assessment: The roundtable will focus on early-stage development, CMC activities, and clinical manufacturing infrastructure, emphasizing laboratory access, CMC and analytical capabilities, and GMP manufacturing for clinical supply, which are foundational for efficient development and regulatory readiness.
- Global Trends Analysis: The discussion will consider global trends shaping biopharma manufacturing, including increasing complexity of biologic modalities and evolving regulatory expectations, helping participants understand how Israel's competitiveness in biopharma may evolve over the next 5-10 years.
- Diverse Participation: Representatives from government, public agencies, Israeli and international biopharma manufacturers, and CDMOs are expected to participate, reflecting the industry's emphasis on the importance of biopharma manufacturing infrastructure and collaboration needs.
Continue Reading